Operates a chain of drug stores across various regions in Japan. Sells prescription and over-the-counter medications to the public. Now — the numbers.
This is an established company with proven profits.
Average growth of 10% a year over the last 4 years. Every year shown ended in profit.
The gap is $111.6M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 14.1× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 10% a year on average.
It pays out $0.52 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.